{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:56:17Z","timestamp":1792180577605,"version":"4.4.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Imatinib (IM) is the primary treatment for Gastrointestinal stromal tumor (GIST), but it faces significant challenges with resistance and a high incidence of adverse events. This study aims to assess the predictive value of baseline body composition parameters on treatment-related adverse events and disease-free survival (DFS) in GIST patients treated with imatinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A single-center retrospective analysis was conducted on 107 moderate or high-risk stratification GIST patients diagnosed from 2014 to 2020 at the First Affiliated Hospital of Nanjing Medical University. Body composition parameters, including skeletal muscle index (SMI), myosteatosis, cachexia index (CXI), and Fat-Free Mass (FFM), etc. were obtained using abdominal CT images and clinical data. Logistic and COX regression models were used to analyze the relationship between these indicators and treatment-related adverse events and DFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multivariate analysis revealed that myosteatosis (OR=7.640, P&amp;lt;0.001) and drug dose (OR=1.349, P=0.010) were independent risk factors for adverse events, while a higher CXI (OR=0.983, P=0.017) was protective. Additionally, LAMA\/SMA% (OR=1.072, P=0.028) was identified as an independent risk factor for dose-limiting toxicity (DLT). Independent predictors of DFS included sarcopenia (HR=3.067, P=0.013), myosteatosis (HR=6.985, P=0.024), risk stratification (HR=9.562, high-risk vs. moderate-risk, P=0.003), and C-KIT mutation (HR=3.615, C-KIT exon 9 mutation vs. 11, P=0.013).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Baseline body composition parameters, particularly myosteatosis, effectively predict the adverse events and DFS in patients taking imatinib. Personalized treatment, such as targeted nutritional and exercise interventions, and close monitoring of patients with myosteatosis or sarcopenia can enhance compliance and improve survival rates.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1576834","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:10:53Z","timestamp":1743999053000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Tianhao","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"iv267","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies","volume":"40","author":"Soreide","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3644","article-title":"Incidence of gastrointestinal stromal tumor in Chinese urban population: A national population-based study","volume":"10","author":"Xu","year":"2021","journal-title":"Cancer Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7344","article-title":"GI stromal tumors: 15 years of lessons from a rare cancer","volume":"33","author":"Cioffi","year":"2015","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9705","article-title":"Gastrointestinal stromal tumors","volume":"36","author":"von Mehren","year":"2018","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy309","article-title":"Translational insights into gastrointestinal stromal tumor and current clinical advances","volume":"29","author":"Hemming","year":"2018","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(02)80608-6","article-title":"Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group","author":"van Oosterom","year":"2002","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","article-title":"Practical management of tyrosine kinase inhibitor-associated side effects in GIST","volume":"37","author":"Joensuu","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx815","article-title":"Insulin resistance and body composition in cancer patients","author":"Dev","year":"2018","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.09.006","article-title":"Sarcopenia in overweight and obese patients is a predictive factor for postoperative complication in gastric cancer: A prospective study","volume":"43","author":"Lou","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12274","article-title":"Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer","volume":"9","author":"Choi","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-05054-3","article-title":"Change in skeletal muscle following resection of stage I-III colorectal cancer is predictive of poor survival: A cohort study","volume":"43","author":"Hopkins","year":"2019","journal-title":"World J Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e328337d826","article-title":"Epidemiology of myosteatosis","volume":"13","author":"Miljkovic","year":"2010","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glv016","article-title":"Muscle quality and muscle fat infiltration in relation to incident mobility disability and gait speed decline: the age, gene\/environment susceptibility-reykjavik study","volume":"70","author":"Reinders","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.878472","article-title":"Impact of baseline muscle mass and myosteatosis on the development of early toxicity during first-line chemotherapy in patients with initially metastatic pancreatic cancer","volume":"12","author":"Hong","year":"2022","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4137\/CMO.S30891","article-title":"Shi R.Cachexia index in advanced non-small-cell lung cancer patients","volume":"9","author":"Jafri","year":"2015","journal-title":"Clin Med Insights Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.1038\/s41598-022-11736-1","article-title":"Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy","volume":"12","author":"Goh","year":"2022","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"106165","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case\u2013control studies in surgery","volume":"96","author":"Mathew","year":"2021","journal-title":"Int J Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17588359231192388","DOI":"10.1177\/17588359231192388","article-title":"2023 GEIS Guidelines for gastrointestinal stromal tumors","volume":"15","author":"Serrano","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1061044","article-title":"Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"B27","volume-title":"BMI classification percentile and cut off points","author":"Weir","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/COC.0000000000000061","article-title":"Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib","volume":"40","author":"Cushen","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp605","article-title":"Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma","volume":"21","author":"Antoun","year":"2010","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12678","article-title":"Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies","volume":"12","author":"Martin","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.05.006","article-title":"Cancer cachexia: Diagnosis, assessment, and treatment","volume":"127","author":"Sadeghi","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00854","article-title":"Genetic polymorphisms and adverse events on unbound imatinib and its active metabolite concentration in patients with gastrointestinal stromal tumors","volume":"10","author":"Qian","year":"2019","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-009-0525-8","article-title":"Gastrointestinal stromal tumor: a bridge between bench and bedside","volume":"12","author":"Nishida","year":"2009","journal-title":"Gastric Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12885-022-09278-w","article-title":"Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor","volume":"22","author":"Song","year":"2022","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010182","article-title":"Impact of sarcopenia and myosteatosis in non-cirrhotic stages of liver diseases: similarities and differences across aetiologies and possible therapeutic strategies","volume":"10","author":"Cespiati","year":"2022","journal-title":"Biomedicines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/S0954422417000051","article-title":"Similarities and interactions between the ageing process and high chronic intake of added sugars","volume":"30","author":"Gatineau","year":"2017","journal-title":"Nutr Res Rev"},{"key":"B38","doi-asserted-by":"publisher","first-page":"b3692","DOI":"10.1136\/bmj.b3692","article-title":"Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials","volume":"339","author":"Bischoff-Ferrari","year":"2009","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jamda.2017.05.026","article-title":"Minerals and sarcopenia; the role of calcium, iron, magnesium, phosphorus, potassium, selenium, sodium, and zinc on muscle mass, muscle strength, and physical performance in older adults: A systematic review","volume":"19","author":"van Dronkelaar","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"B40","doi-asserted-by":"publisher","first-page":"155639","DOI":"10.1016\/j.metabol.2023.155639","article-title":"Sarcopenic obesity: emerging mechanisms and therapeutic potential","volume":"146","author":"Axelrod","year":"2023","journal-title":"Metabolism"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1576834\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:11:10Z","timestamp":1743999070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1576834\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1576834"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1576834","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"article-number":"1576834"}}